Cost-Effectiveness
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis
Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness